GlassScriptPhysician profile
Alison Roostaeyan
NPI 1346738689
$3,979.99
in general payments reported to CMS, 2019-2025
33 companies · $913 in 2025
The $913 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $305 · 2022: $943 · 2023: $953 · 2024: $866 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,633 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,632.97 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $772.03 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $458.44 | 2021-2025 | Jardiance, Synjardy |
| Astellas Pharma US INC | $458.11 | 2022-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals LP | $396.82 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $292.88 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Glaxosmithkline, LLC. | $247.70 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Dexcom, INC. | $190.48 | 2022-2025 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $168.51 | 2022-2025 | Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $149.76 | 2022-2025 | Trintellix |
| Abbott Laboratories | $133.81 | 2022 | |
| Sumitomo Pharma America, INC. | $79.00 | 2024-2025 | Gemtesa |
| Pfizer INC. | $70.63 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $60.19 | 2021-2023 | |
| Exact Sciences Corporation | $58.01 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $55.25 | 2022-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $50.60 | 2021-2022 | |
| Hologic Sales and Service, LLC | $39.58 | 2024 | Thinprep 2000 Processor, Aptima |
| Novartis Pharmaceuticals Corporation | $37.20 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $29.05 | 2022 | |
| Sage Therapeutics, LLC | $26.93 | 2025 | Zurzuvae |
| Edwards Lifesciences Corporation | $22.14 | 2023 | |
| Janssen Pharmaceuticals, INC | $21.02 | 2022 | |
| Sanofi Pasteur INC. | $20.95 | 2023 | |
| Phathom Pharmaceuticals, INC. | $17.78 | 2025 | Voquezna |
| Dynavax Technologies Corporation | $17.60 | 2023 | Heplisav-B |
| Medtronic, INC. | $13.94 | 2023 | Intellis Adaptivestim |
| Axsome Therapeutics, INC. | $13.52 | 2025 | Symbravo |
| Merck Sharp & Dohme LLC | $13.37 | 2023 | Steglatro, Belsomra, Segluromet |
| Currax Pharmaceuticals LLC | $13.31 | 2023 | Contrave |
| Antares Pharma, INC. | $13.24 | 2024 | Xyosted |
| Shield Therapeutics INC | $13.20 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.70 | 2022 | |
| Sunovion Pharmaceuticals INC. | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Roostaeyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.